The treatment landscape for cutaneous fibrosis in North America is evolving steadily, supported by advanced healthcare infrastructure and a strong focus on research and innovation. Increasing prevalence of fibrotic skin disorders such as keloids, scleroderma, and graft versus host disease related fibrosis is driving demand for effective therapeutic solutions. Healthcare providers across the...